AUPH / Aurinia: Redemption On Lupkynis Sales And Possible EMA Approval

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH ) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET Company Participants Jamie Harrell - Investor more_horizontal

Aurinia Pharmaceuticals (AUPH) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares more_horizontal

Here we discuss why investing in Aurinia Pharmaceuticals (AUPH) stock now may be a prudent move. more_horizontal

Aurinia Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapies for diseases with high unmet medical need. more_horizontal

Aurinia Pharmaceuticals, an autoimmune disease specialist, is trading lower on high volume today. The biotech's shares have been trading at a premium more_horizontal

Aurinia Pharmaceuticals (AUPH) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares more_horizontal

Aurinia (AUPH) surges as management decides to explore strategic business options, including potential sale or a merger. more_horizontal

Aurinia (AUPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the more_horizontal